Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
February 17 2021 - 7:30AM
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company
dedicated to the development of innovative therapeutics for
neurotology, today announced multiple presentations at the upcoming
Association for Research in Otolaryngology (ARO) 44th Annual
MidWinter Meeting, to be held virtually February 20-24, 2021. These
include participation in an invited symposium, presentation of the
previously disclosed positive top-line clinical results for OTO-313
in tinnitus and OTO-413 in hearing loss, and multiple presentations
related to Otonomy’s preclinical programs.
“We are pleased to have the opportunity to present clinical
results for OTO-313 and OTO-413 during ARO, which is the premier
meeting of research scientists in the neurotology field,” said Alan
Foster, Ph.D., Vice President, Research of Otonomy. “Additionally,
our multiple presentations this year highlight the breadth of our
pipeline and provide supportive data for our preclinical programs
including OTO-825, a gene therapy for congenital hearing loss, and
OTO-510, an otoprotectant for cisplatin-induced hearing loss.”
Otonomy is participating in a symposium entitled “From bench to
bedside – translational oto-therapeutic approaches” that will be
held from 12:30 to 2:30 p.m. EST on February 24. The Otonomy
presentation topic and presenter are as follows:
- “From research to preclinical development: translating in
vitro/ex vivo research into clinically relevant in vivo studies for
hearing loss” by Bonnie Jacques, Ph.D.
All other Otonomy presentations are during poster sessions
occurring from 3 to 5 p.m. EST on the days indicated below.
Presentations related to Otonomy’s clinical programs for
tinnitus and hearing loss:
- "A Phase 1/2 study of OTO-313 given as a single intratympanic
injection in patients with moderate to severe, persistent tinnitus”
by Maxwell et al., on February 23.
- "A first-in-human study of OTO-413, an intratympanic
sustained-exposure formulation of BDNF, for the treatment of
speech-in-noise hearing impairment” by Anderson et al., on February
23.
Additional presentations related to Otonomy's preclinical
hearing loss programs:
- "Characterization of novel AAV capsid variants for delivery of
GJB2 gene therapy for congenital hearing loss" a joint presentation
from Otonomy and Applied Genetics Technology Corporation (AGTC) by
Uribe et al., on February 24.
- “Identification and characterization of a novel therapeutic
class for protection against cisplatin-induced hearing loss” by
Tsivkovskaia et al., on February 21.
- “Characterization of a TrkB mAb agonist for the treatment of
speech-in-noise hearing difficulties (cochlear synaptopathy)” by
Tsivkovskaia et al., on February 22.
- “Novel tools to probe neurotrophic signaling in cochlear
neurons: fab fragments derived from Trk-selective agonist
monoclonal antibodies are potent and selective antagonists of the
TrkB and TrkC receptors” by Siegel et al., on February 22.
About OtonomyOtonomy is a biopharmaceutical
company dedicated to the development of innovative therapeutics for
neurotology. The company pioneered the application of drug delivery
technology to the ear in order to develop products that achieve
sustained drug exposure from a single local administration. This
approach is covered by a broad patent estate and is being utilized
to develop a pipeline of products addressing important unmet
medical needs including Ménière’s disease, hearing loss, and
tinnitus. For additional information please visit
www.otonomy.com.
Contacts:
Media Inquiries:Spectrum ScienceChloé-Anne RamseyVice
President404.865.3601cramsey@spectrumscience.com
Investor Inquiries:Westwicke ICRRobert H. UhlManaging
Director858.356.5932robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Apr 2023 to Apr 2024